AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its ...

Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing ...

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Immatics N.V. (NASDAQ:IMTX) is among the best German stocks to buy according to analysts. On March 5, Immatics N.V.

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Once-daily zasocitinib significantly improves skin clearance in patients with moderate to severe plaque psoriasis compared with placebo. Topline results were announced from two phase 3 trials ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.

Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP ...

Ocular Therapeutix targets retinal diseases, focusing on wet age-related macular degeneration (AMD) with its lead candidate, AXPAXLI (OTX-TKI). Current wet AMD treatment is dominated by anti-VEGF ...